Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Therapies: Review of Literature and Case Reports FOREWORD

被引：0
|
作者：
Magro, Fernando [1 ,2 ,3 ]
机构：
[1] Portuguese Grp Studies Inflammatory Bowel Dis, Oporto, Portugal
[2] Hosp Sao Joao, Dept Gastroenterol, Oporto, Portugal
[3] Univ Porto, Fac Med, Inst Pharmacol & Therapeut, P-4003 Oporto, Portugal
来源：
BIODRUGS | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1 / 2
页数：2
相关论文
共 50 条
  • [41] Anti-Tumor Necrosis Factor Alpha Antibodies for Remission Maintenance Therapy in Inflammatory Bowel Disease
    Neubauer, Katarzyna
    Kempinski, Radoslaw
    Poniewierka, Elzbieta
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2010, 19 (02): : 143 - 149
  • [42] Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives
    Blam, ME
    Stein, RB
    Lichtenstein, GR
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (07): : 1977 - 1997
  • [43] Anti-Tumor Necrosis Factor Agents in Inflammatory Eye Disease
    Lowder, Careen
    Choudhary, Maria
    Hajj-ali, Rula
    Srivastava, Sunil
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [44] Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease
    Ioannis Androulakis
    Christos Zavos
    Panagiotis Christopoulos
    George Mastorakos
    Maria Gazouli
    World Journal of Gastroenterology, 2015, 21 (47) : 13205 - 13211
  • [45] Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation
    Bortlik, Martin
    Duricova, Dana
    Machkova, Nadezda
    Hruba, Veronika
    Lukas, Martin
    Mitrova, Katarina
    Romanko, Igor
    Bina, Vladislav
    Malickova, Karin
    Kolar, Martin
    Lukas, Milan
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (02) : 196 - 202
  • [46] The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease
    Koutroubakis, Ioannis E.
    Ramos-Rivers, Claudia
    Regueiro, Miguel
    Koutroumpakis, Efstratios
    Click, Benjamin
    Schwartz, Marc
    Swoger, Jason
    Baidoo, Leonard
    Hashash, Jana G.
    Barrie, Arthur
    Dunn, Michael A.
    Binion, David G.
    INFLAMMATORY BOWEL DISEASES, 2015, 21 (07) : 1587 - 1593
  • [47] Pediatric inflammatory bowel disease: Fecal calprotectin response to Anti-tumor necrosis factor alpha
    Manar Matar
    Rachel Levi
    Maya Zvuloni
    Raanan Shamir
    Amit Assa
    Pediatric Research, 2023, 93 : 131 - 136
  • [48] TREATMENT PATTERNS OF ANTI-TUMOR NECROSIS FACTOR AND ANTI-INTEGRIN THERAPIES IN INFLAMMATORY BOWEL DISEASE (IBD): ANALYSIS OF US INSURANCE CLAIMS
    Reddy, Sheila
    Chang, Eunice
    Tarbox, Marian
    Broder, Michael S.
    Best, Jennie
    Pan, Wayne
    GASTROENTEROLOGY, 2018, 154 (06) : S838 - S839
  • [49] Risks of Serious Infection or Lymphoma With Anti-Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: A Systematic Review
    Dulai, Parambir S.
    Thompson, Kimberly D.
    Blunt, Heather B.
    Dubinsky, Marla C.
    Siegel, Corey A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1443 - 1451
  • [50] The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies
    Rubin, David T.
    Griffith, Jenny
    Zhang, Qisu
    Hepp, Zsolt
    Keshishian, Allison
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (08) : 1201 - 1209
12345